Medicure Provides Corporate Update

WINNIPEG, MANITOBA, Jul 22 (MARKET WIRE) --
Medicure Inc. (TSX: MPH), a cardiovascular-focused biopharmaceutical
company, today provided an update on its cash position and commercial
operations.

As a result of the ongoing restructuring and numerous cost containment
endeavors, the Company now expects its cash position will be sufficient
to fund operations to the end of calendar 2008. The Company is currently
exploring further alternatives for strengthening its financial position.

"I am pleased that the Company has been able to reduce its expenses while
still preserving and seeing some positive signs in its AGGRASTAT(R)
business," commented Medicure's President and CEO, Albert D. Friesen,
PhD. "Although we have dramatically reduced our clinical and R&D
headcount we have retained a strong core team of people with the
capabilities to pursue preclinical and clinical development opportunities
involving new potential applications of MC-1, both cardiovascular and
non-cardiovascular, and our portfolio of novel antithrombotic small
molecules."

About Medicure Inc.

Medicure Inc is a biopharmaceutical company focused on the research,
development and commercialization of novel compounds to treat
cardiovascular disorders. Cardiovascular medicine represents the largest
pharmaceutical sector, with annual global sales of over US $70 billion.
Medicure aims to make a global impact on cardiovascular disease and
stroke by reducing deaths, improving the quality of life and serving the
unmet needs of people who suffer from cardiovascular disease and stroke.

This press release contains forward-looking statements, as defined under
applicable securities legislation, that involve risks, which may cause
actual results to differ materially from the statements made, and
accordingly may be deemed to be forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The forward-looking statements are made as of the date
hereof, and the Company disclaims any intention and has no obligation or
responsibility to update or revise any forward-looking statements,
whether as a result of new information, future events, or otherwise
except as required by law. Such forward-looking statements involve known
and unknown risks, uncertainties and other factors that may cause the
actual results, events or developments to be materially different from
any future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, among others, the
Company's stage of development, lack of product revenues, additional
capital requirements, risks associated with the completion of clinical
trials and obtaining regulatory approval to market the Company's
products, the ability to protect its intellectual property, dependence on
collaborative partners and the ability to meet its debt obligations.
These factors should be considered carefully and readers are cautioned
not to place undue reliance on such forward-looking statements.
Additional risks and uncertainties relating to the Company and its
business can be found in the "Risk Factors" section of its Form 20F for
the year ended May 31, 2007 and the Company's MD&A for the third quarter
ended February 29, 2008.

Contacts:
Medicure Inc.
Albert D. Friesen
President & CEO
Toll Free: 1-888-435-2220
(204) 488-9823 (FAX)
Email: info@medicure.com
Website: www.medicure.com

Copyright 2008, Market Wire, All rights reserved.

-0-